Group 1 - The fourth session of the Supervisory Board of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd. was held on July 11, 2025, with all three supervisors present [1][2] - The Supervisory Board approved the adjustment of the price related to the 2023 restricted stock and stock option incentive plan, in compliance with relevant laws and regulations [1][2] - The decision to cancel part of the restricted stock and revoke some stock options was also approved, ensuring no substantial impact on the company's financial status or operational results [2] Group 2 - The voting results showed unanimous support with 3 votes in favor, and no votes against or abstentions [2] - The adjustments made do not require submission to the shareholders' meeting as authorized by the first temporary shareholders' meeting of 2024 [1][2]

Meeting Information - The company will hold its second extraordinary general meeting of shareholders in 2025 on July 28, 2025, at 14:30 [1] - Network voting will also take place on the same day, with specific time slots for voting through the Shenzhen Stock Exchange trading system and internet voting system [1] Voting Procedures - Shareholders can choose either on-site voting or network voting, but not both; if duplicate votes are cast, the first vote will be considered valid [2] - Only ordinary shareholders registered by the cut-off date are eligible to attend and vote, and they may appoint proxies to represent them [2][4] Agenda Items - The meeting will discuss several proposals, including adjustments to the board of directors and amendments to the company's articles of association [3][4] - Certain proposals require a special resolution, needing more than two-thirds of the voting rights held by attending shareholders, while others require a simple majority [4] Registration and Attendance - Registration for the meeting will occur on July 25, 2025, with specific times and location provided for shareholders to complete the registration process [5] - Attendees must bring relevant identification documents for registration [5] Voting Process - The voting will be non-cumulative, and shareholders can express their opinions as agree, disagree, or abstain [6] - Detailed procedures for voting through the Shenzhen Stock Exchange systems are provided, including identity verification requirements [6]

Group 1 - The company has nominated Ms. Jiang Qian as a candidate for the fourth board of directors as a non-independent director, pending approval at the upcoming shareholders' meeting [1][2] - The company plans to add one employee representative director to enhance its corporate governance structure, which is in compliance with relevant laws and regulations [1][2] - The election of Mr. Liu Gaofeng as the employee representative director has been approved by the employee representative assembly, with his term starting upon the approval of the relevant proposals at the shareholders' meeting [2] Group 2 - Ms. Jiang Qian, born in March 1988, has no overseas permanent residency and holds a bachelor's degree; she has previously worked at Yongqing Environmental Protection Co., Ltd. and is currently the secretary of the board [2][3] - Mr. Liu Gaofeng, born in June 1980, also has no overseas permanent residency and holds a bachelor's degree; he has served as a business manager at Amgen Shanghai and is currently the general manager of Hunan Dajia Weikang Pharmaceutical Co., Ltd. [4] - Both candidates do not hold shares in the company and have no related party relationships with major shareholders or other board members, ensuring compliance with legal requirements for board membership [3][4]

Core Viewpoint - The legal opinion letter from Hunan Qiyuan Law Firm confirms that Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.'s adjustments to its 2023 restricted stock and stock option incentive plan, including the cancellation of certain stocks and options, comply with relevant laws and regulations [1][8]. Group 1: Approval and Authorization - The adjustments, cancellations, and authorizations related to the incentive plan were approved by the company's board and do not require further shareholder approval [4][6]. - The legal opinion asserts that necessary approvals and authorizations have been obtained, aligning with the Management Measures and the company's articles of association [8]. Group 2: Price Adjustment Details - The company will distribute a cash dividend of RMB 0.818 per share, totaling RMB 16,801,981.76, based on a total share capital of 205,403,200 shares as of December 31, 2024 [4][5]. - The adjusted grant price for the second category of restricted stock is set at RMB 6.7982 per share, down from RMB 6.88, while the stock option exercise price is adjusted to RMB 13.6782 per share from RMB 13.76 [5][6]. Group 3: Cancellations of Stocks and Options - A total of 120,000 shares of restricted stock and 280,000 stock options will be canceled due to the departure of four incentive targets, reducing the number of eligible participants from 33 to 29 [6][8]. - If the company's performance targets are not met, additional stocks and options will be canceled, with 576,000 shares and 1,344,000 options potentially affected [7][8].

Core Viewpoint - The company announced the cancellation of certain restricted stocks and the termination of stock options as part of its 2023 incentive plan due to the departure of four incentive recipients, which has been approved through the necessary procedures [1][3][6] Summary by Sections Approval Procedures - The company has completed the necessary approval processes for the incentive plan, including the review and verification by the supervisory board [1][2] Cancellation and Termination Details - A total of 4 individuals who were part of the incentive plan have left the company, leading to the cancellation of 45,600 shares of restricted stock and the termination of 1,064,000 stock options that were not yet vested [3][5] Impact on Financials and Operations - The cancellation of the unvested restricted stocks and the termination of stock options will not have a significant impact on the company's financial status or operational results, nor will it affect the stability of the management team or the continuation of the incentive plan [5][6] Opinions from Committees - The Compensation and Assessment Committee supports the cancellation and termination actions, stating they comply with relevant regulations and the incentive plan [5][6] Legal Compliance - The legal opinion confirms that the actions taken regarding the cancellation and termination of stocks and options have received the necessary approvals and comply with applicable laws and regulations [6]

重药控股（000950）公告，预计2025年1月1日至2025年6月30日归属于上市公司股东的净利润为2.6亿元 —3亿元，同比增长9.2%—26%。扣除非经常性损益后的净利润为2.5亿元—2.8亿元，同比增长14.39%— 28.12%。基本每股收益为0.15元/股—0.17元/股。 ...

Group 1: Business Overview - The company primarily engages in pharmaceutical commerce, warehousing logistics, pharmaceutical manufacturing, and R&D, with pharmaceutical commerce as the core business. In 2024, the revenue distribution was 95.03% for wholesale and 4.59% for retail [2] - Revenue from pharmaceutical products and medical devices accounted for 82.11% and 15.82% respectively in 2024 [2] - The company is expanding into emerging business areas such as medical aesthetics, special medical foods, veterinary drugs, health products, and radioactive drugs [2] Group 2: Financial Performance - Financial costs decreased due to a declining trend in financing interest rates influenced by recent national monetary policies [3] - The company’s credit has improved since joining the General Technology Group, leading to a significant expansion of financing channels and a noticeable decline in financing costs since 2024 [3] Group 3: Business Collaboration - Since joining the General Technology Group, the company has accelerated collaboration with over 400 medical institutions, having opened accounts in 104 and initiated supply chain services in 93 [4] Group 4: Medical Device Sector - The medical device business includes a wide range of products such as medical devices, equipment, consumables, diagnostic reagents, IVD, and orthopedic products, with consumables being the largest category. The revenue from medical devices accounted for 15.82% in 2024 [5] Group 5: Retail Sector - The retail pharmacy segment includes community health pharmacies and DTP prescription pharmacies, with 776 community pharmacies and 181 DTP pharmacies covering 22 provinces and municipalities by the end of 2024. The retail segment's revenue accounted for 4.59% in 2024 [6] - The company plans to enhance its retail channel construction and develop a comprehensive marketing service network to provide diverse health services [6] Group 6: Market Value Management - The company places high importance on market value management and has recently disclosed a market value management system. Future plans include optimizing the equity structure and selecting suitable market value management tools to enhance investment value [7]

Group 1: ETF Performance and Liquidity - The 300 Dividend Low Volatility ETF recorded an intraday transaction of 32.3471 million yuan, with an average daily transaction of 1.56 billion yuan over the past week as of July 9 [3] - The latest scale of the 300 Dividend Low Volatility ETF reached 5.739 billion yuan, with a net inflow of 143 million yuan recently [3] - Over the past five trading days, there were three days of net inflow totaling 156 million yuan [3] Group 2: Historical Returns and Rankings - As of July 9, the 300 Dividend Low Volatility ETF has seen a net value increase of 61.15% over the past five years, ranking 43rd out of 995 index equity funds, placing it in the top 4.32% [3] - The highest monthly return since inception was 13.89%, with the longest consecutive monthly gain being five months and a maximum increase of 14.56% [3] - The average return during the rising months was 3.66%, and the ETF outperformed the benchmark with an annualized return of 7.10% over the last three months [3] Group 3: Top Holdings - As of June 30, 2025, the top ten weighted stocks in the CSI 300 Dividend Low Volatility Index include China Shenhua, Gree Electric, Sinopec, Daqin Railway, Shuanghui Development, Midea Group, China State Construction, China Mobile, China Merchants Jinling, and Huayu Automotive, collectively accounting for 35.21% of the index [3] Group 4: Market Insights - CITIC Securities indicated that the market will enter the earnings disclosure period in July, with recent performance in the dividend sector suggesting that funds may focus on uncovering investment opportunities around earnings [6] - Investors without stock accounts can access investment opportunities through the corresponding CSI 300 Dividend Low Volatility ETF linked fund (007606) [6]

证券代码：600713 证券简称：南京医药 编号：ls2025-097 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为保证南京医药股份有限公司 2024 年度第二期中期票据（债券简称：24 南 京医药 MTN002，债券代码：102483420.IB）付息工作的顺利进行，现将有关事 宜公告如下： 一、本期债券基本情况 | 发行人名称 | 南京医药股份有限公司 | | | --- | --- | --- | | 债项名称 | 南京医药股份有限公司 2024 年度第二期中期票据 | | | 债项简称 | 24 南京医药 | MTN002 | | 债项代码 | 102483420.IB | | | 发行总额（亿） | 10.00 | | | 起息日 | 2024-08-09 | | | 发行期限（年） | 5 | | | 债券余额（亿） | 10.00 | | | 最新评级情况 | AA+ | | | 偿还类别 | 利息支付 | | | 本计息期债项利率 | 2. ...

本文源自：金融界 安徽华人健康医药股份有限公司的主营业务是医药零售、代理及终端集采业务。公司的主要产品是中西 成药、中药饮片、保健品、医疗器械、特色原料药等。2024年度，公司营业收入再创新高，达45.32亿 元，比上年同期增长19.34%；归属于母公司所有者的净利润为1.38亿元，比上年同期增长20.09%；归属 于母公司所有者的扣除非经常性损益净利润1.29亿元，比上年同期增长21.81%，其中研发费用为 2,938.73万元，比上年同期增长21.46%。公司经营性现金流量持续改善，经营质量稳步提升。 最新一期业绩显示，2025年一季报，公司实现营业收入12.67亿元，同比14.71%；净利润6122.23万元， 同比28.15%，销售毛利率33.58%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13华人健康38.1641.892.7957.68亿行业平均 45.3234.252.13111.08亿行业中值28.2424.671.3862.81亿1柳药集团8.217.990.8868.33亿2九州通 9.0110.561.00264.73亿3鹭燕医药10.189.811.0533.92亿4英 ...